Five-year progression of unilateral age-related macular degeneration to bilateral involvement: the Three Continent AMD Consortium report

Purpose To assess the 5-year progression from unilateral to bilateral age-related macular degeneration (AMD) and associated risk factors. Design Pooled data analyses of three prospective population-based cohorts, the Blue Mountains Eye Study, Beaver Dam Eye Study and Rotterdam Study. Methods Retinal photography and interview with comprehensive questionnaires were conducted at each visit of three studies. AMD was assessed following the modified Wisconsin AMD grading protocol. Progression to bilateral any (early and late) or late AMD was assessed among participants with unilateral involvement only. Factors associated with the progression were assessed using logistic regression models while simultaneously adjusting for other significant risk factors. Results In any 5-year duration, 19–28% of unilateral any AMD cases became bilateral and 27–68% of unilateral late AMD became bilateral. Factors associated with the progression to bilateral involvement of any AMD were age (per year increase, adjusted OR 1.07), carrying risk alleles of the complement factor H and age-related maculopathy susceptibility 2 genes (compared with none, OR 1.76 for 1 risk allele and OR 3.34 for 2+ risk alleles), smoking (compared with non-smokers, OR 1.64 for past and OR 1.67 for current smokers), and the presence of large drusen area or retinal pigmentary abnormalities in the first eye. Conclusion One in four to one in five unilateral any AMD cases, and up to one in two unilateral late AMD cases, progressed to bilateral in 5 years. Known AMD risk factors, including smoking, are significantly associated with the progression to bilateral involvement.

[1]  R. Klein,et al.  The Wisconsin age-related maculopathy grading system. , 1991, Ophthalmology.

[2]  Gabriëlle H S Buitendijk,et al.  Harmonizing the Classification of Age-related Macular Degeneration in the Three-Continent AMD Consortium , 2014, Ophthalmic epidemiology.

[3]  Paul Mitchell,et al.  Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. , 2002, Ophthalmology.

[4]  Gabriëlle H S Buitendijk,et al.  Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. , 2014, American journal of ophthalmology.

[5]  Gabriëlle H S Buitendijk,et al.  Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium. , 2013, Ophthalmology.

[6]  J. J. Wang,et al.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. , 1995, Ophthalmology.

[7]  R. Klein,et al.  American Journal of Epidemiology Original Contribution Combined Effects of Complement Factor H Genotypes, Fish Consumption, and Inflammatory Markers on Long-term Risk for Age-related Macular Degeneration in a Cohort , 2022 .

[8]  Gabriëlle H S Buitendijk,et al.  Genetic susceptibility, dietary antioxidants, and long-term incidence of age-related macular degeneration in two populations. , 2014, Ophthalmology.

[9]  Johanna M Seddon,et al.  Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. , 2011, Ophthalmology.

[10]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[11]  Sandra S Stinnett,et al.  Vision-related quality of life in patients with bilateral severe age-related macular degeneration. , 2005, Ophthalmology.

[12]  R. Klein,et al.  Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. , 2003, Ophthalmology.

[13]  A. Hofman,et al.  Cholesterol and age-related macular degeneration: is there a link? , 2004, American journal of ophthalmology.

[14]  Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group. , 1993, Archives of ophthalmology.

[15]  B. Rosner,et al.  Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. , 2010, Ophthalmology.

[16]  Ronald Klein,et al.  Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study. , 2015, JAMA ophthalmology.

[17]  R. Klein,et al.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. , 2002, Ophthalmology.

[18]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[19]  R. Klein,et al.  Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. , 2002, American journal of epidemiology.

[20]  A Hofman,et al.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study. , 2001, Investigative ophthalmology & visual science.

[21]  A. Hofman,et al.  Age-related macular degeneration and smoking. The Rotterdam Study. , 1996 .

[22]  Luigi Ferrucci,et al.  Evaluation of real-world mobility in age-related macular degeneration , 2015, BMC Ophthalmology.

[23]  A. Hofman,et al.  The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. , 2003, Archives of ophthalmology.

[24]  Paul Mitchell,et al.  Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. , 2007, Ophthalmology.

[25]  G. Abecasis,et al.  Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test? , 2015, Ophthalmology.

[26]  A. Hofman,et al.  Age-Related Macular Degeneration and Smoking , 2017 .

[27]  R. Klein,et al.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. , 1997, Ophthalmology.

[28]  Chelsea E. Myers,et al.  Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study. , 2013, JAMA ophthalmology.